---
schema_version: "secwatch.filing_event.v1"
accession: "0000771856-25-000022"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2025-09-15T23:59:59+00:00"
generated_at: "2026-05-17T06:41:48.850868+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology Q1 FY2026 revenue $14.0M; adjusted EBITDA $60K vs $2.0M; CEO Rob Brainin appointed

## Summary
- Revenue $14.0M, down from $14.1M YoY; operating loss of $527K vs income of $1.3M.
- Adjusted EBITDA fell to $60K from $2.0M; gross margin 43% vs 50%.
- Rob Brainin appointed CEO; previously CEO? He signs report as CEO as of Sept 15, 2025.
- Cash on hand $10.3M with no debt; net cash from operations $600K.

## SEC filing metadata
- accession: 0000771856-25-000022
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2025-09-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000077185625000022/0000771856-25-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000077185625000022/csbr-20250915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000771856-25-000022
- JSON: https://secwatch.observer/filing/0000771856-25-000022.json
- Plain text: https://secwatch.observer/filing/0000771856-25-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.